ZPL-389
Phase 2- Indications
- Atopic dermatitis
Company intelligence / Profile preview
Ziarco Pharma Ltd
Sandwich, England, United Kingdomnovartis.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lead compound ZPL-389 (H4 receptor antagonist) showed clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile
- Therapeutic areas
- NeurologyImmunologyDermatologyPulmonology
- Modalities
- Small moleculesoral and topical formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Pfizer (licensed assets from Pfizer)
Beyond the preview
Go deeper on Ziarco Pharma Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ziarco Pharma Ltd.